Milbemite (Canada)This page contains information on Milbemite for veterinary use.
The information provided typically includes the following:
- Milbemite Indications
- Warnings and cautions for Milbemite
- Direction and dosage information for Milbemite
MilbemiteThis treatment applies to the following species:
(milbemycin oxime 0.1% ear solution)
A topical medication for the treatment of otoacariasis caused by Otodectes cynotis, in dogs and cats, puppies and kittens.
Novartis Animal Health encourages you to take the time to read this package insert which describes the use of MILBEMITE (milbemycin oxime) for the treatment of ear mite infestations due to Otodectes cynotis in dogs and cats.
MILBEMITE is only available through veterinarians.
MILBEMITE is available as a liquid in plastic dispensing tubes with break off tips for administration to dogs and cats, puppies and kittens 2 weeks of age or older (see dosage section). Open the tube by pressing cap down firmly to break seal. Remove cap and check to be sure tip of tube is open. Each plastic tube contains 0.25 mL of MILBEMITE as 0.1% solution of milbemycin oxime. 0.05 mL of the volume in the tubes is retained in the tube after administration. Milbemycin oxime consists of the oxime derivatives of 5-didehydromilbemycins in the ratio of approximately 80% A4 (C32H45NO7, MW 555.71) and 20% A3 (C31H43NO7, MW 541.68).
MILBEMITE is indicated for treatment of parasitic infestations of the external ear by removal of the ear mite, Otodectes cynotis, in dogs, cats, puppies, and kittens two weeks of age or greater.
Ear Mite Disease In Dogs And Cats
Otodectes cynotis is an ear mite that infests the external ear canal and skin of dogs and cats causing intense irritation. Otodectic otitis is manifested by copious production of dark cerumen. The animal may rub and scratch its ears and shake its head violently causing damage to the external ear possibly resulting in aural hematoma. Protracted infestation with Otodectes cynotis may cause rupture of the tympanic membrane leading to disease of the middle ear or central nervous system.
Animals with ear mite disease may infest other animals in the household.
MILBEMITE should be administered according to the following schedule.
Recommended Dosage Schedule
2 tubes per ear (0.4 mL delivered)
0.1% milbemycin oxime
1 tube per ear (0.2 mL delivered)
0.1% milbemycin oxime
Note: a small amount of residual volume (0.05 mL) will remain in the dispensing tube.
MILBEMITE should be administered as one tube per ear in cats, and 2 tubes per ear in dogs, as a single treatment. Ear cleaning is recommended prior to instilling each tube. Follow-up evaluation should be performed 7-10 days post treatment. In a small number of cases, retreatment may be indicated based on follow-up examinations. It is important to treat all affected pets in the household.
Milbemycin oxime, the active ingredient of MILBEMITE, is a macrocyclic lactone derivative which is believed to act by interfering with invertebrate neurotransmission.
Safety & Efficacy
Safety: Multiple studies were conducted to evaluate the safety of a 0.1% milbemycin oxime solution for the treatment of ear mite infestations (Otodectes cynotis) in adult dogs and cats. In each study, repeated topical doses at 1, 3 or 5x the recommended dose did not produce adverse effects. This includes the product when used in microfilaria (Dirofilaria immitis) positive dogs. In addition, no measurable levels of the milbemycin were detected in whole blood of the dogs and cats dosed at 5x. Oral dosing on a daily basis of 3x the recommended oral dose of milbemycin oxime has been proven safe in over 75 different breeds of dogs including collies, pregnant females, breeding males and females, and puppies over two weeks of age.
Efficacy: The clinical efficacy of milbemycin oxime 0.1% was evaluated in a placebo-controlled dose confirmation study of client-owned cats and dogs. Ears were examined for clinical signs of mite infestation (i.e. evidence of excessive ear exudate, head shaking, pruritus, erythema, and/or alopecia). Otodectes cynotis infestation was diagnosed by direct microscopic visualization of ear swab debris. Test or placebo treatment was administered to both ears of the animal following the pre-treatment examination. Animals’ ears were examined by ear swab microscopy at 7-10 days and at 28-35 days post-treatment.
In dogs, eighty-six (86.2) percent of the milbemycin oxime treated group were ear mite negative at 7-10 days post treatment. This percentage increased to 93.1% at 28-35 days post treatment.
In cats, ninety-nine percent (99%) of the milbemycin oxime treated group were ear mite negative at 7-10 days post treatment. This 99% efficacy was maintained through the next evaluation at 28-35 days post treatment.
In summary, the current studies demonstrate that milbemycin oxime provides safe, and effective removal of ear mites in dogs and cats.
This product has not been tested in puppies or kittens less than two weeks of age.
Many animals treated for otoacariasis have concurrent otitis externa involving secondary yeast or bacterial infections. Otodectes cynotis causes primary inflammation and pruritus of the external ear canal and predisposes to these secondary infections. Therefore, cats and dogs with otoacariasis complicated by secondary yeast and/or bacterial infections may require supportive therapy in addition to a treatment with an acaricide.
Keep out of reach of children. If accidentally swallowed, call a physician.
MILBEMITE is supplied as individual white polypropylene tubes, paired in a foil overlay envelope. There are 2 tubes of 0.25 mL each in one foil pouch, then 10 cartons in an outer box.
MILBEMITE should be stored at room temperature between 15° and 25°C.
Novartis Animal Health Canada Inc., 2233 Argentia Road, Floor 2, Suite 205, West Tower, Mississauga, Ontario L5N 2X7
® Milbemite is a registered trademark of Novartis AG: Novartis Animal Health Canada Inc., licensed user
© 2010 Novartis Animal Health Canada Inc.
NAC No.: 12310623
2000 ARGENTIA RD., SUITE 400, PLAZA 3, MISSISSAUGA, ON, L5N 1V9
|Every effort has been made to ensure the accuracy of the Milbemite information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.|
Copyright © 2014 North American Compendiums. Updated: 2014-12-03